Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
3 ratings / 3.33 average

Pharmacotherapeutic Options for Pulmonary Arterial Hypertension

Myung H Park, MD

Pulmonary hypertension (PH) was first described by the German physician Ernst von Romberg as “sclerosis of the pulmonary arteries” in 1891, and was considered to be a uniformly fatal disease with an expected survival of <3 years [1,2]. However, an explosion of progress over the past 30 years has resulted in tremendous advances in the understanding of the pathobiology and mechanisms of this disease, through which have developed a systematic approach for diagnosis and eight approved therapies for pulmonary arterial hypertension (PAH). This review will focus on current concepts of mechanisms, diagnostic strategies, and treatment approaches for PAH.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles